Latest Advances in Oncology: Scientific Review

Cancer's manipulation of the immune system

Researchers from MSK and Weill Cornell Medicine have discovered that cancer can manipulate the STING immune pathway. This alteration suppresses anti-tumor immunity, aiding cancer metastasis. This finding could reshape the approach to STING agonist drugs in clinical trials.

Read the article

Advancements in liquid biopsy technologies

Liquid biopsy technologies are revolutionizing precision oncology. These technologies analyze biological fluids for early cancer detection and personalized treatment. The 7th Annual Liquid Biopsy for Precision Oncology Summit highlighted the progress and challenges in this area.

Read the article

Understanding glioblastoma's resistance to immunotherapy

While some tumors that metastasize to the brain respond to immunotherapy, glioblastoma remains resistant. Research from Emory University suggests that lymph nodes play a pivotal role in this differential response. The study emphasizes the potential of enhancing T cell activation as a prospective treatment strategy.

Read the article

Chemotherapy's Unintended Awakening of Breast Cancer Cells

Chemotherapy might inadvertently awaken dormant breast cancer cells, leading to renewed growth. The awakening is driven by the release of two cell-signaling cytokines following the impact of chemotherapy on stromal cells. This discovery suggests a new treatment approach combining a MEK inhibitor with docetaxel.

Read the article

Scientific Application Note

DRUG TARGETS: A novel ATR inhibitor has cleared phase I development with manageable toxicity; responses were seen in tumours harbouring ATM/ARID1A and BRCA1 alteration (colorectal and ovarian respectively)

Jun 29th

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors Published online June 22, 2020. AbstractPURPOSE Preclinical studies demonstrated that ATR inhibition can...

Scientific Application Note

PANCREATIC CANCER: Addition of a PARP inhibitor (veliparib) to gemcitabine + cisplatin chemo did not improve outcomes for patients harbouring germline mutations in BRCA1/2 or PALB2

May 11th

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation Journal of Clinical Oncology May 01, 2020 ABSTRACT PURPOSEFive percent to 9% of pancreatic ductal...

Scientific Application Note

RENAL CANCER In a retrospective analysis, rechallenge with immunotherapy delivered ORR 23% (compared with 37% ORR for first exposure); responses at rechallenge were not restricted to those who had responded at first exposure.

Jun 22nd

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma IMPORTANCE Several immune checkpoint inhibitors (ICIs) are approved for use in patients with metastatic renal cell carcinoma (mRCC), but the...

Scientific Review: Latest Discoveries in Oncology

Cancer's manipulation of the immune system

Advancements in liquid biopsy technologies

Understanding glioblastoma's resistance to immunotherapy

Chemotherapy's Unintended Awakening of Breast Cancer Cells

You may also be interested in these resources

DRUG TARGETS: A novel ATR inhibitor has cleared phase I development with manageable toxicity; responses were seen in tumours harbouring ATM/ARID1A and BRCA1 alteration (colorectal and ovarian respectively)

PANCREATIC CANCER: Addition of a PARP inhibitor (veliparib) to gemcitabine + cisplatin chemo did not improve outcomes for patients harbouring germline mutations in BRCA1/2 or PALB2

RENAL CANCER In a retrospective analysis, rechallenge with immunotherapy delivered ORR 23% (compared with 37% ORR for first exposure); responses at rechallenge were not restricted to those who had responded at first exposure.